Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Presentation (August 2020)
17 slides from Staar Surgical's investor presentation, Aug 11, 2020
Slide 1: STAAR Surgical Company Investor presentation
STAAR Surgical Company Investor presentation August 11-12, 2020 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, plans, strategies, and objectives of management for 2020 or prospects for achieving su
Slide 3: The Future of Refractive Surgery is Lens-Based... The Time for STAAR is Now
The Future of Refractive Surgery is Lens-Based... The Time for STAAR is Now Large and Growing Addressable Market (TAM) Strong Financial Performance includes Expanding Margins and Cash Generation Proprietary Lens Technology and Business Model is Driving Industry-Leading Growth
Slide 4: TAM: STAAR is Targeting Two Large Markets
TAM STAAR is Targeting Two Large Markets Refractive Today: 4 Million Procedures Annually (Market Scope) Refractive Future: Growth refueled by lens-based myopia and presbyopia solutions Myopia Presbyopia * Company estimates of Viable Market Opportunity. Adjustments to TAM based on Epidemiological Dat
Slide 5: TAM Tailwinds Will Drive Future Market Growth
TAM Tailwinds Will Drive Future Market Growth …to dramatically increase STAAR’s Opportunity. Significant and Increasing Prevalence… Patients Require Correction Myopia Presbyopia 75-80% of 45-54 Year Olds are Using Correction for Presbyopia** $70 Billion Spend * BHVI, adapted from Holden et al. 2016
Slide 6: Proprietary Lens-Based Technology
Proprietary Lens-Based Technology Over 1 Million ICLs™ Implanted Globally Please Note: The ICL is not visible to other people after implantation. * EVO ICL Patient Registry data on file. 99.4% of Patients Would Elect STAAR’s EVO Implantable Collamer® Lens Again* An Evolution in Visual Freedom™
Slide 7: ICL Advantages
ICL Advantages Proprietary Lens-Based Technology Natural Crystalline Lens Iris Cornea ICL™ Retina Proprietary Collamer Material Quality of Vision Removeable Eco-Friendly Bio-Compatible No Dry Eye Syndrome Upgradeable No Capital Investment Excellent Night Vision Quiet in the Eye Additive UV Protectio
Slide 8: Industry Leading Growth: Revenue and Growth Y/Y
$82.4 Million 7% Growth 2016 $90.6 Million 10% Growth 2017 $124.0 Million 37% Growth 2018 $150.2 Million 21% Growth 2019 Industry Leading Growth Three-Year 22% CAGR* Revenue and Growth Y/Y * Three-Year compound annual growth rate (CAGR) calculated from 2016-2019.
Slide 9: Industry Leading Growth: ICL Unit Growth
Industry Leading Growth ICL Unit Growth Y/Y*… Fiscal Year 2019 * Select markets for the Twelve-Months Ended January 3, 2020.
Slide 10: Industry Leading Growth Drives Expanding Margins and EPS
Industry Leading Growth Drives… Gross Margin Operating Margin GAAP EPS * Includes $0.07 GILTI tax benefit for FY2019. Expanding Margins Expanding GAAP EPS Profitability
Slide 11: Cash Generation and Strong Balance Sheet
Industry Leading Growth Drives… Cash from Operations ($ Millions) FYE Balance Sheet Cash* ($ Millions) Cash Generation Strong Balance Sheet * The Company closed an underwritten offering of common stock for total net proceeds of approximately $72.1 million in August 2018. Cash, cash equivalents and r
Slide 12: STAAR's Global Eyeprint
STAAR’s Global “Eyeprint” 75 Countries Globally STAAR operates with independent distribution in the remaining countries where the ICL is sold. Hybrid Markets: China | S. Korea | India Potential Future Hybrid Markets Direct Markets: United States | Canada | U.K. | Germany | Spain | Japan
Slide 13: ICL Global Market Share
ICL Global Market Share * Company estimates as of October 24, 2019. Estimated market share as a percentage of the 4 million total global procedures annually and by market. The Top 2 markets, China and the U.S., represent approximately 1.75 million total annual procedures. Approximately 6% and Growin
Slide 14: STAAR's Execution: Promises Made. Promises Kept.
STAAR’s Execution Three-Year Financial Outlook Provided at November 2017 Investor Day and Execution… Promises Made. Promises Kept. GAAP EPS Outlook 2018 - 2020 Annual Revenue Growth of 15 - 20% Stretch Annual ICL Unit Growth of 25%+ Profitability Improvement; Achieve Sustainable Positive EPS within
Slide 15: STAAR's Vision 2020-2022 Strategic Imperatives
STAAR’s Vision 2020-2022 Strategic Imperatives Provided at November 2019 Investor Day Position EVO Implantable Lenses as a Special and Transformational Pathway to Visual Freedom… Promote Exceptional Desirability to Win Consumer Choice and Social Media Enthusiasm Support the Transformation of the Ref
Slide 16: Recent Highlights
Recent Highlights STAAR welcomed two new Board members with deep ophthalmic expertise, Dr. Gil Kliman and Tom Frinzi, on June 1 and a new Chief Financial Officer, Patrick F. Williams, on July 6. Reported 2Q results demonstrate STAAR’s ability to perform well in the midst of a prolonged shutdown of e
Slide 17: The Future of Refractive Surgery is Lens-Based. The Time for STAAR is Now!
The Future of Refractive Surgery is Lens-Based. The Time for STAAR is Now! www.staar.com www.discoverevo.com